|
Patent landscape, scope, and claims: |
United States Patent 7,119,106 Landscape, Claim Scope, and Competitive Patent Risks
US Patent 7,119,106 is a broad composition-of-matter claim family anchored to “a compound of the formula” (structure not provided in the prompt) presented as the active ingredient or an acid-addition salt, combined with a pharmaceutically acceptable carrier for multiple administration routes. Claim scope is driven by (i) generic formula coverage of the active compound and (ii) wide excipient/carrier language, with narrower boundaries introduced by route-of-administration and specific dose/ concentration ranges in dependent claims. The practical litigation and generic design-around risk hinges on whether competitors use (a) a covered formula compound or (b) an unclaimed structural variant, plus whether their dosage form and exposure window fall inside the asserted oral/parenteral and dose range limits.
What the independent claim covers (Claim 1)
Claim 1 is a classic “composition” claim with a structural tether:
- A pharmaceutical composition containing:
- an effective amount of a compound “of the formula” (or an acid addition salt), and
- a pharmaceutically acceptable carrier/diluent/excipient.
Scope implications
- Core infringement trigger: manufacture or sale of any oral or injectable dosage containing the claimed compound (or its acid-addition salt) at an “effective amount,” formulated with typical pharmaceutical carriers.
- Excipients are not limiting: carrier, diluent, or excipient is broad; most standard formulations for tablets/capsules/injectables will fall within it.
- “Effective amount” is functional and relatively elastic: it is not constrained by a numeric mg value in Claim 1, so competitive exposure at clinically effective dosing can satisfy the claim.
What the dependent claims narrow (Claims 2–7)
Claims 2–4 narrow to oral dosage forms and a numeric dose band; Claims 5–7 narrow to parenteral sterile solution and a concentration band.
- Claim 2: Claim 1 composition “suitable for oral administration.”
- Claim 3: Claim 2 is “in the form of a tablet or a capsule.”
- Claim 4: Claim 3 wherein the compound is present in an amount of 1 to 100 mg.
- Claim 5: Claim 1 suitable for parenteral administration.
- Claim 6: Claim 5 comprises a “sterile injectable solution.”
- Claim 7: Claim 6 wherein the compound is present in a concentration of 20 to 100 mg/mL.
Scope implications by dependent layer
- Oral route and solid dosage (Claims 2–3): Adds formulation and dosage form specificity. If a generic uses the same active compound and dose but offers it as a different oral form (eg, solution, suspension, chewable, film), it may argue it does not meet “tablet or capsule.”
- Numeric dose band (Claim 4): The range 1–100 mg can capture many strength presentations, but it also gives a design-around vector via strengths outside the range (eg, 0.5 mg or 150 mg per unit) if such a presentation avoids claim construction that “the compound is present in an amount of 1 to 100 mg” on a per-unit basis.
- Parenteral route and sterile solution (Claims 5–6): “Sterile injectable solution” excludes some parenteral presentations (eg, suspensions, powders for reconstitution, lyophilized products) unless construed to cover them. It is a relatively important limiter.
- Concentration band (Claim 7): 20–100 mg/mL is a strong numeric boundary. Competitors can reduce or increase concentration via formulation changes or dose volume strategies to land outside the claimed band.
How strong is the patent estate for US 7,119,106: what claims actually risk infringement?
High-risk coverage zones
- Any dosage form that contains the claimed formula compound or acid-addition salt at an effective amount, formulated with standard excipients (Claim 1).
- Tablet/capsule oral products containing the compound at 1–100 mg per unit (Claims 2–4).
- Sterile injectable solutions containing the compound at 20–100 mg/mL (Claims 5–7).
Key weak points for an asserted composition claim
- Structure tether is decisive: Claim 1 depends on “a compound of the formula.” Without the specific formula in Claim 1, the scope cannot be mapped precisely. In practice, this is where validity and infringement typically turn: whether a competitor’s API is literally within the formula or falls under permissible equivalents.
- Dose-form and range dependencies create factual levers:
- Oral “tablet or capsule” is a narrow dosage-form limiter.
- Parenteral “sterile injectable solution” can be avoided with alternative parenteral formats if the competitor’s product is not a solution.
- Numeric concentration and dose ranges can be avoided by altering strength/concentration.
What does the “compound of the formula” limitation mean for infringement risk?
Literal infringement mechanics
- A competitor must have, in the accused product, a compound that satisfies the formula definition in Claim 1, or one of its acid addition salts.
- “Pharmaceutically acceptable carrier/diluent/excipient” is not a meaningful barrier because nearly all commercial formulations satisfy this.
Practical infringement mapping approach used in US litigation
- Claim construction focuses on:
- formula interpretation,
- what qualifies as an acid addition salt of the claimed compound,
- and how “effective amount,” “tablet or capsule,” and concentration ranges are treated.
Design-around vectors
- Substitute an API that falls outside the formula range.
- Use a different salt form if “acid addition salt” is constrained by claim construction (salt definition is often litigated).
- Alter presentation:
- oral: avoid tablet/capsule; consider other oral forms.
- parenteral: avoid sterile injectable solution (move to lyophilized, powder for reconstitution, or other parenteral form factors).
- shift strengths/concentrations outside the numeric ranges.
Which formulations are protected by US 7,119,106 (oral vs parenteral)?
Oral formulation coverage (Claims 2–4)
Protected categories:
- oral administration,
- tablet or capsule dosage forms,
- 1–100 mg compound per unit.
What is arguably excluded
- oral liquids, suspensions, chewables, implants, suppositories, transdermal systems, or other dosage forms not captured by “tablet or capsule.”
- tablet/capsule strengths outside 1–100 mg per unit, depending on claim construction of “present in an amount of 1 to 100 mg.”
Parenteral formulation coverage (Claims 5–7)
Protected categories:
- parenteral administration,
- sterile injectable solution,
- 20–100 mg/mL concentration.
What is arguably excluded
- sterile injectable suspensions (not “solution”),
- lyophilized powders requiring reconstitution (not a “solution” at time of administration unless claim is construed broadly),
- infusion concentrates shipped as non-solution intermediates, if the final product at administration is outside the claimed concentration band.
When does US 7,119,106 lose exclusivity and what are the FDA timing triggers?
This section cannot be completed accurately from the information provided. Patent term and exclusivity depend on the application filing date, patent issuance date, any patent term adjustment (PTA), any terminal disclaimer, and whether regulatory exclusivity applies to the underlying drug. FDA marketing timing also requires identifying:
- the NDA/BLA product tied to the claimed compound,
- the approval date,
- and whether it lists in the Orange Book against US 7,119,106.
No product identifier, drug name, or FDA application number is provided, so a complete and accurate exclusivity timeline is not possible here.
What generic entry risks exist for products using the same “formula compound”?
Primary generic risk
- A Paragraph IV certification against an Orange Book listing tied to US 7,119,106 (if applicable) would target the exact API/formulation coverage:
- same formula compound or acid-addition salt,
- in a tablet/capsule strength 1–100 mg, or sterile injectable solution at 20–100 mg/mL,
- and formulated with typical carriers.
Secondary generic risk
- Even if the generic changes dosage form or concentration:
- Claim 1 still exists and can capture “effective amount” compositions unless the design-around avoids the dependent claim limitations while still infringing Claim 1’s broader composition structure.
Litigation posture typically seen
- Competitors challenge formula scope and salt definition.
- Asserted product design-around arguments concentrate on:
- dosage form category (tablet/capsule vs other),
- solution vs suspension,
- numeric ranges.
How does US 7,119,106 compare with other typical composition patents (range-limited dependent claims)?
US 7,119,106 fits a common strategy:
- Independent claim is broad on “compound of formula + carrier + effective amount.”
- Dependent claims narrow by route, dosage form, and numeric dose/concentration.
Competitive implication
- Broad Claim 1 makes “carrier and formulation” a poor design-around lever.
- Competitors must rely on:
- API structure not covered by the formula, or
- dosage form category and concentration/dose ranges not meeting the dependent claim limits, and
- claim construction narrowing that makes “tablet or capsule” and “sterile injectable solution” restrictive.
What patent litigation affects US 7,119,106?
This cannot be produced accurately without:
- the drug identity tied to US 7,119,106,
- the assignee,
- and the Orange Book listing record or PACER/Docket mapping by patent number and related cases.
No such inputs are provided in the prompt, so litigation impact cannot be stated.
What is the Orange Book status of US 7,119,106?
Orange Book status requires identification of:
- the specific drug product,
- the listed active ingredient(s),
- and the listed patents (and their patent claim coverage) associated with approved NDA/BLA.
The prompt does not include the drug name, application number, or Orange Book listing details. A correct Orange Book status statement cannot be made.
Key Takeaways
- US 7,119,106 Claim 1 broadly covers pharmaceutical compositions containing an “effective amount” of a “compound of the formula” or an acid addition salt plus standard carriers.
- Dependent claims materially narrow to:
- oral tablet/capsule at 1–100 mg, and
- parenteral sterile injectable solution at 20–100 mg/mL.
- Infringement risk concentrates on whether a competitor’s API falls within the formula and whether its dosage form/concentration matches the dependent claim boundaries.
- Exclusivity, Orange Book status, and litigation impact cannot be determined from the claim text alone.
FAQs
-
How can a generic design around a tablet/capsule range of 1–100 mg?
By offering a non-tablet/capsule oral form or strengths outside the per-unit 1–100 mg band, subject to claim construction.
-
Does “effective amount” in Claim 1 capture all marketed doses?
It captures any amount that is clinically effective for the intended therapeutic use, with disputes usually centered on claim construction and factual dosing evidence.
-
Can a competitor avoid Claims 5–7 by using a lyophilized parenteral product?
Potentially, if the product is not a “sterile injectable solution” at the relevant point in the commercialization and administration chain.
-
What role does the definition of “acid addition salt” play in infringement?
Salt characterization can determine whether a competitor’s solid form remains within the claimed scope or is a non-covered salt form.
-
If the API is outside the formula, can infringement still occur under Claim 1?
If the API does not satisfy the formula limitation (or a covered acid-addition salt definition), Claim 1’s compound element is not met.
References (APA)
No sources were provided or cited in the prompt.
More… ↓
⤷ Start Trial
|
